Back Hepatitis C

Hepatitis C

EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks

Two injections of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks led to 12-week post-treatment sustained response in 97% of chronic hepatitis C patients, according to study results presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

EASL 2016: Sofosbuvir/ Ledipasvir for 6 Weeks Cures Acute Hepatitis C in HIV-Negative People

A regimen of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured all patients with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to findings from a German study presented this week at the 2016 EASL International Liver Congress in Barcelona. The researchers said treating hepatitis C early with a short regimen would improve symptoms sooner, prevent HCV transmission, and cost less than treatment initiated during chronic infection.

alt

EASL 2016: Hepatitis C Treatment May Not Stop Progression to Advanced Liver Disease

Doctors need to have full and frank discussions with patients about the potential risks and benefits of using direct-acting antivirals (DAAs) to treat hepatitis C in late-stage liver disease, especially among those waiting for a liver transplant, liver specialists said at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.alt

EASL 2016: Low-Cost Generic Hepatitis C Drugs Match Branded Products in Viral Response

Generic versions of direct-acting antivirals for hepatitis C purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as the branded products, a study of 139 patients monitored by Australian doctor James Freeman has shown. The findings were presented in a late-breaking research session at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona on Saturday.

alt

EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis

Leaders of liver disease associations from Europe, the U.S., Latin America, and Asia released a Joint Society Statement on Elimination of Viral Hepatitis at the opening session of the International Liver Congress (EASL 2016) this week in Barcelona, calling for enhanced efforts to diagnose and treat hepatitis B and C, with the goal of eliminating viral hepatitis as a public health threat.

alt

EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability

Hepatitis C treatment managed by non-specialists such as primary care physicians and nurse practitioners is as safe and effective as treatment delivered by specialists -- even for challenging patient groups -- and could help increase the number of people receiving therapy, according to findings from the ASCEND study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials

The Drugs for Neglected Diseases Initiative (DNDi) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with all genotypes of hepatitis C virus (HCV). The combination, manufactured by Egyptian company Pharco, could be made available for $300 for a course of treatment if it proves safe and effective, DNDi executive director Bernard Pécoul announced ahead of the 2016 EASL International Liver Congress this week in Barcelona. The studies will aim to test an affordable pangenotypic combination and to provide data for regulatory submission.

alt

EASL 2016: International Liver Congress Underway this Week in Barcelona

The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.

alt